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Abstract A new series of 2,6,9-trisubstituted adenines (5–
14) have been prepared and evaluated in radioligand
binding studies for their affinity at the human A1,A 2A
and A3 adenosine receptors and in adenylyl cyclase
experiments for their potency at the human A2B subtype.
From this preliminary study the conclusion can be drawn
that introduction of bulky chains at the N
6 position of 9-
propyladenine significantly increased binding affinity at the
human A1 and A3 adenosine receptors, while the presence
of a chlorine atom at the 2 position resulted in a not
univocal effect, depending on the receptor subtype and/or
on the substituent present in the N
6 position. However, in
all cases, the presence in the 2 position of a chlorine atom
favoured the interaction with the A2A subtype. These results
demonstrated that, although the synthesized compounds
were found to be quite inactive at the human A2B subtype,
adenine is a useful template for further development of
simplified adenosine receptor antagonists with distinct
receptor selectivity profiles.
Keywords Adeninederivatives.Adenosinereceptors.
Adenosinereceptor antagonists.Adenosinereceptor
ligands.Gprotein-coupledreceptors
Introduction
Adenosine, a naturally occurring nucleoside, is involved in
a wide variety of physiological and pathophysiological
processes [1]. Adenosine mediates these effects through the
activation of at least four human receptor subtypes (P1),
belonging to the superfamily of G protein-coupled recep-
tors, which have been recently cloned [2] and classified as
A1,A 2A,A 2B and A3 [3]. The subtypes are classified on the
bases of coupling to second messengers and pharmacolog-
ical profiles for agonists and antagonists. In fact, A1 and A3
adenosine receptor subtypes are linked to inhibition of
adenylyl cyclase and A2A and A2B subtypes are linked to
stimulation of the same enzyme [4].
In particular, A2B receptors have been implicated in
several physiological functions such as the regulation of
mast cell secretion [5, 6], gene expression [5, 7, 8], cell
growth [9] and intestinal functions. A2B receptors may also
play a role in asthma, since they mediate mast cell
degranulation from human mast cells and are present in
high density in human blood eosinophils [10, 11]. For this
reason A2B antagonists could be considered potential
antiasthmatic agents [10–12]. While the A1,A 2A and A3
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terized through the use of highly potent and selective
agonists and/or antagonists, an accurate investigation of the
pathophysiological role of A2B receptors is precluded due
to the lack of very selective ligands [13]. On the other hand,
only recently radiolabelled adenosine antagonists have been
used for binding assays at the A2B receptor subtype [1].
Recently, xanthine derivatives, such as compounds 1 and 2
in Fig. 1, have been proposed as potent and selective
adenosine receptor antagonists [14, 15]. On the other hand,
in the non-xanthine family poor results have been obtained
in recent years. However, mention should be made of the
pyrazolo-triazolo-pyrimidine derivative 3, which showed
promising binding affinity at the A2B adenosine receptor
although the level of selectivity vs the human (h) A3
subtype was still poor [16]. Very recently, a bipyrimidyl
derivative 4 has been proposed as an A2B adenosine
receptor antagonist, with affinity in the same range of
compound 3, while the selectivity vs the other receptor
subtypes was found to be significantly better [17] (Fig. 1).
A structural analysis of the derivatives 1 and 3 clearly
shows the presence of bulky substituents such as arylox-
yacetylamino-phenyl groups at the 8 position (compound 1)
and arylacetyl moiety at the N5 position (compound 3).
On the other hand, in recent years a number of substituted
adenines have been synthesized and tested at the four
adenosine receptor subtypes, demonstrating that the introduc-
tion of different substituents at the 2, 8 and 9 positions of the
adenine core resulted in high-affinity antagonists with distinct
receptor selectivity profile [18–22]. At the A2B receptor the
derivatives bearing an ethyl in the 9 position and linear chains
in the 2 position showed potency in the μM range, while the
presence of sterically hindered substituents in the same
positions was detrimental for the potency. Furthermore,
substitution of the 9-ethyl group with a propyl chain seems
to favour the interaction with human A2B receptors [21].
Hence, on the basis of the results obtained with
compound 3, introduction of a bulky substituent on the N
6
amino group of the adenine and 2-chloroadenine moiety
could increase potency and selectivity for the human A2B
adenosine receptor subtypes.
Hence, bulky substituents such as arylacetyl or arylox-
yphenylacetyl moieties were introduced on the N
6 amino
group of compounds 5 and 6 to obtain derivatives 7–14,
Fig. 1 Structures and binding
profile (Ki nM) of some A2B
adenosine receptor antagonists
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(Fig. 2).
Chemistry
The designed compounds (5–14) have been synthesized as
summarized in Schemes 1 and 2. The starting 9-propyla-
denine (5)[ 23] was obtained by alkylation of commercially
available adenine (15) with propyliodide in the presence of
potassium carbonate. Flash chromatography led to the
desired 9-substituted isomer 5 as the major product (yield
79%) together with the 7-isomer 5a (yield 9%). Isomeric
structure of compounds 5 and 5a was assigned on the bases
of 1D-
1H-NOE difference spectra. In fact, irradiation of
both CH2 groups of the propylic chain in compound 5a
gave a NOE at both H-C(8) and 6-NH2 groups, demon-
strating the 7 position as the alkylation site. On the
contrary, a NOE at both H-C(8) and H-C(2), and not at
the 6-NH2 group in compound 5, upon saturation of CH2
groups of the propylic chain, confirmed the 9 position as
the alkylation site.
The 2-chloro derivative 6 was obtained by alkylation of
commercially available 2,6-dichloropurine (16) with pro-
pyliodide, using the same procedure utilized for compound
5, to afford the 9-substituted isomer 17 as the major product
(yield 75%) along with the 7-isomer 17a (yield 10%) [24].
[
1H]-NMR spectra of 17 and 17a in CDCl3 are in
agreement with those reported in the literature [24]; in the
experimental part [
1H]-NMR spectra of the same com-
pounds are reported using dimethyl sulfoxide (DMSO) as
the solvent. Compound 17 was reacted with liquid
ammonia in a sealed tube at room temperature (RT)
overnight to give the 2-chloro-9-propyladenine (6)[ 24]
(Scheme 1).
Final compounds 7–14 were obtained by condensation
of amino compounds 5 or 6 with the appropriate acid 18–22
[25] in the presence of carbonyldiimidazole in tetrahydro-
furane (THF) at reflux for 18 h (Scheme 2).
Results and discussion
All the compounds were evaluated at the human recombi-
nant adenosine receptors, stably transfected into Chinese
hamster ovary (CHO) cells, utilizing radioligand binding
studies (A1,A 2A,A 3) or adenylyl cyclase activity assay
(A2B). Receptor binding affinity was determined using [
3H]
CCPA (2-chloro-N
6-cyclopentyladenosine) as the radio-
ligand for A1 receptors, whereas [
3H]NECA (5’-N-ethyl-
carboxamidoadenosine) was used for the A2A and A3
subtypes. In the case of A2B receptors Ki values were
calculated from IC50 values determined by inhibition of
NECA-stimulated adenylyl cyclase activity. Ki values are in
μM, with 95% confidence intervals in parentheses [26].
The results of binding and cyclase activity studies are
reported in Table 1.
All the tested compounds 5–14 showed affinities at the
human A1,A 2A and A3 adenosine receptors in the μM
range without significant levels of selectivity. At A2B
receptors most compounds were found to be inactive when
tested at a concentration up to 100 μM( K i values >
30 μM). It is quite evident that the introduction of
phenylacetic or aryloxyphenylacetic moieties at the N
6
position of 9-propyladenine (5) or of 2-chloro-9-propyla-
denine (6) to give compounds 7–14 modifies the binding
profile of the derivatives, although without significantly
increasing binding affinity (Table 1). On the other hand, the
same substitutions were found to be detrimental for the
activity at the A2B receptor subtype. In fact, the N
6-
unsubstituted derivative 6 proved to be the most potent of
the series with Ki A2B=11 μM.
The effect of the chlorine at the 2 position on binding
affinity at the adenosine receptors it is not univocal,
depending on the receptor subtype and/or on the substituent
in N
6. Analysis of the binding profile of the N
6-unsub-
stituted derivatives in more detail revealed that the presence
of a chlorine atom at the 2 position (compound 6) increased
the affinity (A1,A 2A and A3) and potency (A2B)a t
adenosine receptors two- to threefold compared with the
unsubstituted analogue 5.
A quite similar profile could be observed when a 4-
bromophenylacetic group was introduced at the N
6 position
(compare compound 8 with 7). Fig. 2 Structures of designed compounds
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at A1,A 2B and A3 receptors when a bulkier substituent,
such as the 4-aryloxyphenylacetic chain, was introduced at
the N
6 position. In fact, this kind of combination
significantly reduced or did not modify the A1 and A3
affinity and the A2B potency (9:K i A1=1.4 μM, Ki A2B >
30 μM, Ki A3=5.3 μMv s10:K i A1=26 μM, Ki A2B>
30 μM, Ki A3=4.9 μMa n d12:K i A1=13 μM, Ki A2B=
22 μM, Ki A3=10 μMv s13:K i A1=22 μM, Ki A2B>
30 μM, Ki A3=19 μM).
However, in all cases, the presence of a chlorine atom
in the 2 position favoured the interaction with the A2A
subtype (compare A2A affinity of 5, 7, 9 and 12 with 6, 8,
10 and 13, respectively), while the presence of any
substituent on the N
6 position seems to somewhat reduce
the affinity. In fact the compound endowed with the
highest A2A affinity proved to be the 2-chloro-9-propyla-
denine (6:K i A2A=2.2 μM). These findings are in
agreement with previous observations related to adenosine
analogues strongly suggesting that the introduction of
substituents in the N
6 position dramatically reduces the
A2A affinity [27–32].
Nevertheless, it should be underlined that the presence of a
bulky chain at the N
6 position significantly increased (20- to
Scheme 1 a Synthesis of
9-propyladenine; b Synthesis of
2-chloro-9-propyladenine.
Reagents: i: DMF, K2 CO3,
propyliodide, RT; ii: liq. NH3,
sealed tube, RT
Scheme 2 Reagents: i: CDI,
dry THF, reflux
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with 9-propyladenine (9:K i A1=1.4 μMa n d11:K i A3=
1.4 μMv s5:K i A1=24 μMa n dK i A3>100 μM).
This increase of affinity seems also to be modulated by
the substituent on the aryloxyphenylacetic group; in fact,
substitution with a lipophilic bromine (9) or methyl group
(11) at the para position is responsible for the increased A1
and A3 receptor affinity, respectively, while the presence of
a hydrogen (12) or a methoxy group (14) did not positively
influence the binding profile.
Conclusions
In conclusion the study herein presented, although it did not
reach the proposed goal of obtaining A2B adenosine
receptor antagonists, increased knowledge of the structure-
activity relationships in adenine derivatives.
Moreover, it was demonstrated that the introduction of
bulky substituents at the N
6 position of adenine derivatives
significantly increased the affinity at the A1 and A3
adenosine receptors, while the presence of a chlorine atom
in the 2 position favoured the interaction with the A2A
subtype. These results demonstrated that, although the
synthesized compounds were found to be quite inactive at
the human A2B subtype, adenine is a useful template for
further development of simplified adenosine receptor
antagonists with distinct receptor selectivity profiles,
opening up new chances to design structurally simplified
A1 and A3 adenosine receptor antagonists.
Experimental section
Chemistry
General: melting points were determined with a Büchi
apparatus and are uncorrected.
1H NMR spectra were
obtained with Varian VXR 300 MHz spectrometer; δ in
ppm, J in Hz. All exchangeable protons were confirmed by
addition of D2O. Thin layer chromatography (TLC) was
carried out on precoated TLC plates with silica gel 60 F-
Table 1 Biological profile of synthesized compounds 5–14
aDisplacement of specific [
3H]-CCPA binding at human A1 receptors expressed in CHO cells.
bDisplacement of specific [
3H]-NECA binding at
human A2A receptors expressed in CHO cells.
cKi values of the inhibition of NECA-stimulated adenylyl cyclase activity in CHO cells expressing
human A2B receptors.
dDisplacement of specific [
3H]-NECA binding at human A3 receptors expressed in CHO cells.
Purinergic Signalling (2007) 3:339–346 343254 (Merck). For column chromatography, silica gel 60
(Merck) was used. Elemental analyses were determined on
Fisons Instruments Model EA 1108 CHNS-O model
analyser and are within ± 0.4% of theoretical values.
9-Propyladenine (5) and 7-propyladenine (5a)
To a solution of adenine (15) (0.5 g, 3.7 mmol) in dry DMF
(10 ml), under nitrogen, K2CO3 (0.83 g, 5.97 mmol) and
propyliodide (0.433 ml, 4.44 mmol) were added. The
mixture was stirred at RT for 16 h, then the solvent was
removed under reduced pressure and the crude purified by
flash chromatography (CHCl3-MeOH 98:2) to afford 5 [23]
and 5a (yield 79 and 9%, respectively) as white solids, after
crystallization from CH3OH.
5: m.p. 173–175°C.
1H-NMR (DMSO-d6) δ 0.85 (t, 3H,
J=7.4, CH3); 1.82 (m, 2H, CH2-CH3); 4.11 (t, 2H, J=7.0,
CH2-N); 7.21 (bs, 2H, NH2); 8.15 (s, 2H, H-2 and H-8).
Anal. Calcd. for C5H5N5 (177.2) C, 54.22; H, 6.26; N,
39.52; found: C, 54.54; H, 6.71; N, 39.33.
5a: m.p. >250°C.
1H-NMR (DMSO-d6) δ 0.86 (t, 3H,
J=7.3, CH3); 1.91 (m, 2H, CH2-CH3); 4.26 (t, 2H, J=7.0,
CH2-N); 7.75 (s, 1H, H-2); 7.85 (bs, 2H, NH2); 8.34 (s, 1H,
H-8). Anal. Calcd. for C5H5N5 (177.2) C, 54.22; H, 6.26;
N, 39.52; found: C, 54.45; H, 6.45; N, 39.45.
2,6-Dichloro-9-propyl-9H-purine (17) and 2,6-dichloro-7-
propyl-9H-purine (17a)
To a solution of 2,6-dichloropurine (16) (1 g, 5.29 mmol) in
dry DMF (14 ml), under nitrogen, K2CO3 (1.18 g,
6.61 mmol) and propyliodide (0.59 ml, 6.08 mmol) were
added. The mixture was stirred at RT overnight, then the
solvent was removed under reduced pressure and the crude
purified by flash chromatography (cC6H12-EtOAc 75:25) to
afford 17 and 17a as white solids (yield 75 and 10%,
respectively) [24].
17: m.p. 58–59°C;
1H-NMR (DMSO- d6) δ 0.86 (t, 3H,
J=7.5 Hz, CH2CH3), 1.85 (m, 2H, CH2CH3), 4.21 (t, 2H,
J=7.0 Hz, N-CH2), 8.76 (s, 1H, H-8). Anal. Calcd. for
C8H8Cl2N4 (231.1) C, 41.58; H, 3.49; N, 24.25. Found: C,
41.85; H, 3.70; N, 24.10.
17a: m.p. 103–105°C;
1H-NMR (DMSO-d6) δ 0.87 (t,
3H, J=7.4 Hz, CH2CH3), 1.84 (m, 2H, CH2CH3), 4.40 (t,
2H, J=7.2 Hz, N-CH2), 8.89 (s, 1H, H-8). Anal. Calcd. for
C8H8Cl2N4 (231.1) C, 41.58; H, 3.49; N, 24.25. Found: C,
41.75; H, 3.55; N, 24.19.
2-Chloro-9-propyladenine (6)
Liquid ammonia (5 ml) and compound 17 (0.46 g,
1.97 mmol) were poured into a sealed tube and the resulting
mixture was stirred at RT overnight. Ammonia was
evaporated and the crude purified by flash chromatography
(CHCl3-MeOH 99:1) to give 6 [24] as a white solid (yield
75%) m.p. 224–226°C.
1H-NMR (DMSO-d6) δ 0.84 (t, 3H,
J=7.3 Hz, CH2CH3), 1.79 (m, 2H, CH2CH3), 4.05 (t, 2H,
J=7.2 Hz, N-CH2), 7.72 (s, 2H, NH2), 8.15 (s, 1H, H-8).
Anal. Calcd. for C8H10ClN5 (211.7) C, 45.40; H, 4.76; N,
33.09. Found: C, 45.75; H, 4.80; N, 32.87.
General procedure for the preparation
of the N
6-acylaminoadenine (7–14)
A solution in dry THF (4 ml) of the appropriate acid (18–
22) (0.46 mmol) and carbonyldiimidazole (83 mg,
0.51 mmol) was poured at reflux under nitrogen for 1 h.
Then the amino compound 5 or 6 (0.46 mmol) was added
and the resulting mixture was refluxed overnight. The
solvent was removed under reduced pressure and the crude
purified by flash chromatography to afford the desired final
compounds 7–14.
6-[(4-Bromophenyl)acetyl]amino-9-propyladenine (7)
Eluent for chromatography CHCl3-MeOH 95:5; yield
59%, white solid; m.p. 149–151°C (dec.);
1H-NMR
(DMSO-d6): δ 0.83 (t, 3H, J=7.2 Hz, CH2CH3), 1.84
(m, 2H, CH2CH3), 3.89 (s, 2H, CH2-CO), 4.19 (t, 2H, J=
7.1 Hz, N-CH2), 7.30 (d, 2H, J= 8 . 4H z ,H - P h ) ,7 . 5 1( d ,
2H, J=8.4 Hz, H-Ph), 8.47 (s, 1H, H-8), 8.62 (s, 1H, H-2),
10.91 (s, 1H, NH). Anal. Calcd. for C16H16BrN5O (374.2)
C, 51.35; H, 4.31; N, 18.71. Found: C, 51.65; H, 4.80; N,
18.50.
6-[(4-Bromophenyl)acetyl]amino-2-chloro-9-
propyladenine (8)
Eluent for chromatography CHCl3-cC6H12 80:20; yield
26%, white solid; m.p. 164–166°C;
1H-NMR (DMSO-d6):
δ 0.84 (t, 3H, J=7.5 Hz, CH2CH3), 1.83 (m, 2H, CH2CH3),
3.88 (s, 2H, CH2-CO), 4.15 (t, 2H, J=6.9 Hz, N-CH2), 7.30
(d, 2H, J=8.4 Hz, H-Ph), 7.53 (d, 2H, J=8.4 Hz, H-Ph),
8.50 (s, 1H, H-8), 11.25 (s, 1H, NH). Anal. Calcd. for
C16H15BrClN5O (408.7) C, 47.02; H, 3.70; N, 17.14.
Found: C, 47.49; H, 3.83; N, 17.40.
6-[(4-(4-Bromobenzyloxy)phenyl)acetyl]amino-9-
propyladenine (9)
Eluent for chromatography CHCl3-MeOH 95:5; yield 58%,
white solid; m.p. 154–156°C;
1H-NMR (DMSO-d6): δ 0.85
(t, 3H, J=7.5 Hz, CH2CH3), 1.85 (m, 2H, CH2CH3), 3.82
(s, 2H, CH2-CO), 4.21 (t, 1H, J=7.0 Hz, N-CH2), 5.07 (s,
2H, CH2-O), 6.95 (d, 2H, J=8.8 Hz, H-Ph), 7.27 (d, 2H, J=
8.4 Hz, H-Ph), 7.40 (d, 2H, J=8.4 Hz, H-Ph), 7.58 (d, 2H,
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10.81 (s, 1H, NH). Anal. Calcd. for C23H22BrN5O2 (480.4)
C, 57.51; H, 4.62; N, 14.58. Found: C, 57.99; H, 4.66; N,
14.55.
6-[(4-(4-Bromobenzyloxy)phenyl)acetyl]amino-2-chloro-9-
propyladenine (10)
Eluent for chromatography CHCl3-cC6H12-MeOH 50:48:2;
yield 14%, white solid; m.p. 176–178°C;
1H-NMR
(DMSO-d6): δ 0.81 (t, 3H, J=7.5 Hz, CH2CH3), 1.79 (m,
2H, CH2CH3), 3.76 (s, 2H, CH2-CO), 4.12 (t, 2H, J=
7.4 Hz, N-CH2), 5.03 (s, 2H, CH2-O), 6.92 (d, 2H, J=
8.6 Hz, H-Ph), 7.22 (d, 2H, J=8.4 Hz, H-Ph), 7.36 (d, 2H,
J=8.4 Hz, H-Ph), 7.54 (d, 2H, J=8.4 Hz, H-Ph), 8.46 (s,
1H, H-8), 11.11 (s, 1H, NH). Anal. Calcd. for
C23H21BrClN5O2 (514.8) C, 53.66; H, 4.11; N, 13.60.
Found: C, 53.75; H, 4.25; N, 13.29.
6-[(4-(4-Methylbenzyloxy)phenyl)acetyl]amino-9-
propyladenine (11)
Eluent for chromatography CHCl3-cC6H12-MeOH 70:28:2;
yield 35%, white solid; m.p.131–132°C;
1H-NMR (DMSO-
d6): δ 0.83 (t, 3H, J=7.3 Hz, CH2CH3), 1.84 (m, 2H,
CH2CH3), 2.28 (s, 3H, CH3-Ph), 3.80 (s, 2H, CH2-CO),
4.20 (t, 2H, J=7.1 Hz, N-CH2), 5.02 (s, 2H, CH2-O), 6.93
(d, 2H, J=8.4 Hz, H-Ph), 7.24 (m, 6H, H-Ph), 8.47 (s, 1H,
H-8), 8.62 (s, 1H, H-2), 10.83 (s, 1H, NH). Anal. Calcd. for
C24H25N5O2 (415.5) C, 69.38; H, 6.06; N, 16.86. Found: C,
69.74; H, 6.35; N, 16.54.
6-[(4-Benzyloxyphenyl)acetyl]amino-9-propyladenine (12)
Eluent for chromatography CHCl3-MeOH 97:3; yield 52%,
white solid; m.p. 121–123°C;
1H-NMR (DMSO-d6): δ 0.83
(t, 3H, J=7.5 Hz, CH2CH3), 1.84 (m, 2H, CH2CH3), 3.80
(s, 2H, CH2-CO), 4.19 (t, 2H, J=7.1 Hz, N-CH2), 5.07 (s,
2H, CH2-O), 6.95 (d, 2H, J=8.4 Hz, H-Ph), 7.25 (d, 2H, J=
8.8 Hz, H-Ph), 7.37 (m, 5H, H-Ph), 8.47 (s, 1H, H-8), 8.62
(s, 1H, H-2), 10.82 (s, 1H, NH). Anal. Calcd. for
C23H23N5O2 (401.5) C, 68.81; H, 5.77; N, 17.44. Found:
C, 68.97; H, 5.89; N, 17.35.
6-[(4-Benzyloxyphenyl)acetyl]amino-2-chloro-9-
propyladenine (13)
Eluent for chromatography CHCl3-MeOH 99:1; yield 17%,
white solid; m.p. 150–152°C;
1H-NMR (DMSO-d6): δ 0.84
(t, 3H, J=7.3 Hz, CH2CH3), 1.82 (m, 2H, CH2CH3), 3.79
(s, 2H, CH2-CO), 4.14 (t, 2H, J=7.0 Hz, N-CH2), 5.07 (s,
2H, CH2-O), 6.95 (d, 2H, J=8.6 Hz, H-Ph), 7.25 (d, 2H, J=
8.4 Hz, H-Ph), 7.37 (m, 5H, H-Ph), 8.49 (s, 1H, H-8), 11.16
(s, 1H, NH). Anal. Calcd. for C23H22ClN5O2 (435.9) C,
63.37; H, 5.09; N, 16.07. Found: C, 63.56; H, 5.14; N,
15.76.
6-{[(4-Methoxybenzyloxy)phenyl]acetyl}amino-2-chloro-9-
propyladenine (14)
Eluent for chromatography CHCl3-MeOH 99:1; yield 29%,
white solid; m.p. 174–176°C;
1H-NMR (DMSO-d6): δ 0.84
(t, 3H, J=7.4 Hz, CH2CH3), 1.82 (m, 2H, CH2CH3), 3.73
(s, 3H, CH3-O), 3.79 (s, 3H, CH2-CO), 4.14 (t, 2H, J=
7.0 Hz, N-CH2), 4.98 (s, 2H, CH2-O), 6.92 (d, 2H, J=
8.0 Hz, H-Ph), 6.93 (d, 2H, J=8.4 Hz, H-Ph), 7.24 (d, 2H,
J=8.4 Hz, H-Ph), 7.35 (d, 2H, J=8.4 Hz, H-Ph), 8.49 (s,
1H, H-8), 11.15 (s, 1H, NH). Anal. Calcd. for
C24H24ClN5O3 (465.9) C, 61.87; H, 5.19; N, 15.03. Found:
C, 61.99; H, 5.33; N, 14.91.
Biology
All pharmacological methods followed the procedures as
described earlier [26]. In brief, membranes for radioligand
binding were prepared from CHO cells stably transfected
with human adenosine receptor subtypes in a two-step
procedure. In a first low-speed step (1,000 g) cell fragments
and nuclei were removed. The crude membrane fraction
was sedimented from the supernatant at 100,000 g. The
membrane pellet was resuspended in the buffer used for the
respective binding experiments, frozen in liquid nitrogen
and stored at −80°C. For the measurement of adenylyl
cyclase activity only one high speed centrifugation of the
homogenate was used. The resulting crude membrane pellet
was resuspended in 50 mM Tris/HCl, pH 7.4 and
immediately used for the cyclase assay.
For radioligand binding at A1 adenosine receptors 1 nM
[
3H]CCPA was used, whereas 30 and 10 nM [
3H]NECA
were used for A2A and A3 receptors, respectively. Non-
specific binding of [
3H]CCPA was determined in the
presence of 1 mM theophylline; in the case of [
3H]NECA
100 pM R-PIA was used. Ki values from competition
experiments were calculated with the program SCTFIT
[33]. At A2B adenosine receptors inhibition of NECA-
stimulated adenylyl cyclase activity was used as a mea-
surement of potency of the new compounds. IC50 values
from these experiments were converted to Ki values with
the Cheng and Prusoff equation [34].
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